8 results about "Tumor immunosuppression" patented technology

This invention discloses a composite nanozyme that enhances the clinical efficacy of oxaliplatin, its preparation method, and its application. The composite nanozyme consists of indium ruthenium nanozyme and an iliximab embedding and anchoring layer. The indium ruthenium nanozyme consists of indium ruthenium nanoparticles and a carbon-nitrogen framework, with the indium ruthenium nanoparticles loaded on the surface and within the pores of the carbon-nitrogen framework. The iliximab embedding and anchoring layer consists of a dithiol polyethylene glycol coating layer and iliximab. Preparation method: ZIF-8 is prepared by co-precipitation of zinc salt methanol solution and 2-methylimidazole methanol solution, followed by calcination to obtain the carbon-nitrogen framework. The carbon-nitrogen framework dispersion is then stirred in an oil bath with indium nitrate solution and ruthenium trichloride solution to prepare a nanozyme precursor, followed by calcination to obtain indium ruthenium nanozyme. The indium ruthenium nanozyme is dispersed in a dithiol polyethylene glycol solution, and iliximab solution is added dropwise. The resulting solid product is then dried. This invention can solve problems such as strong drug tolerance, insufficient intracellular accumulation, and severe tumor immunosuppression in oxaliplatin treatment.

This invention relates to a liposomal formulation based on myeloid cell regulation and chemotherapy enhancement, along with its preparation method and antitumor applications, belonging to the technical field of pharmaceutical formulations. The liposomal formulation uses liposomes as carriers to co-load the CD11b agonist leukadherin-1 (LA1) prodrug (DSPE-PEG2000-Azo-LA1) and the gemcitabine prodrug Gem-SS-Chol. DSPE-PEG2000-Azo-LA1 contains a hypoxia-responsive azobenzene linker, and Gem-SS-Chol contains a glutathione-responsive disulfide bond, enabling precise drug release within the tumor microenvironment. This formulation exhibits uniform particle size and good stability, synergistically exerting chemotherapeutic and immunomodulatory effects. It effectively inhibits the proliferation and migration of pancreatic cancer tumor cells, enhances tumor cell immunogenic cell death, regulates the phenotype of myeloid immune cells in the tumor immunosuppressive microenvironment, and improves the therapeutic effect of pancreatic cancer. This invention provides a novel and highly efficient liposomal formulation for pancreatic cancer treatment, focusing on myeloid cell regulation and chemotherapy enhancement.

This invention discloses a nanocomposite loaded with PD-L1 siRNA and an anti-tumor peptide, its preparation, and its application in treating renal cell carcinoma. The nanocomposite uses a dendritic macromolecule as its carrier, and the loaded peptide is Tat-HSPB1, whose amino acid sequence is shown in SEQ ID NO.1. The amino acid sequence of the loaded PD-L1 siRNA is shown in SEQ ID NO.2. The composite of this invention utilizes multiple interactions between phenylboronic acid, nucleic acids, and peptides to achieve stable co-assembly and acid-responsive intracellular release. While reducing the cytotoxicity of high-generation dendritic macromolecules, it effectively delivers siPD-L1 to specifically downregulate PD-L1 expression in renal tumor cells, thereby relieving tumor immunosuppression. Synergistically, with the anti-tumor activity of Tat-HSPB1 itself, this composite can significantly induce tumor cell death and inhibit its proliferation, providing a novel, highly efficient, and low-toxicity strategy for renal cell carcinoma immunotherapy.

This invention discloses the application of LukS-PV and its combination with a PD-1 inhibitor in the preparation of drugs for treating hepatocellular carcinoma, belonging to the field of biomedical technology. LukS-PV of this invention exerts its anti-tumor effect by promoting the polarization transformation of tumor-associated macrophages from M2 to M1 types, thereby improving the tumor immunosuppressive microenvironment. Furthermore, the combined use of LukS-PV and a PD-1 inhibitor can enhance CD8+ T cell infiltration and anti-tumor immune function, alleviate T cell exhaustion, and improve the therapeutic effect of liver cancer.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

The application discloses a macrophage-loaded nanocomposite anti-tumor targeted drug delivery system and a preparation method and application thereof. The drug delivery system is formed by loading a Toll-like receptor agonist, a photothermal response agent, a phospholipid and cholesterol into a liposome nanoparticle, coating a bacterial outer membrane vesicle on the outer surface of the drug-loaded liposome nanoparticle to form a drug-loaded nanocomposite, and loading the drug-loaded nanocomposite into macrophages through co-incubation. The system of the application uses macrophages and liposomes as carriers, combines immunotherapy and combined phototherapy to improve the immunotherapy effect by inducing immunogenic cell death caused by the photothermal effect, and further promotes the recruitment and accumulation of macrophages through the regulation of the inflammatory tumor microenvironment, generates a positive feedback cycle, and effectively improves the tumor immunosuppressive microenvironment and inhibits tumor growth and metastasis.

The application discloses an anti-LILRB1 / LILRB2 fully human single-domain antibody and a preparation method and application thereof, and obtains the anti-LILRB1 / LILRB2 fully human single-domain antibody which has the function of blocking HLA-G ligand and can be combined with human LILRB1 and LILRB2 proteins on the cell surface. The antibody can be applied to the efficacy of M1 type macrophages existing in a reinforced tumor environment, weakens the inhibition capacity of M2 type macrophages, improves a tumor microenvironment, and reverses tumor immunosuppression mediated by TAM.

The present application relates to a kind of glutathione-responsive exosome biomimetic dendrimer nanogel vaccine and its preparation method and application.The vaccine is loaded with 5-Aza, coated with tumor cell Ex and modified R837 in turn to prepare dendrimer nanogel as carrier.The vaccine realizes precise drug delivery of tumor by virtue of the homologous targeting characteristics of Ex, and can target drug release in response to the high glutathione characteristics of tumor microenvironment.5-Aza exerts epigenetic therapy effect through DNA demethylation, while inducing pyroptosis type ICD of tumor cells.R837 immunoadjuvant can synergize with tumor-associated antigens carried by Ex to promote the maturation of dendritic cells, promote the polarization of M2 type tumor-associated macrophages to M1 type, and reverse the tumor immunosuppressive microenvironment.The present application combines epigenetic therapy and immunotherapy, providing a new strategy for the clinical treatment of pancreatic cancer, and has wide clinical application prospect.